TCGA-E9-A1N8-01A-11R-A144-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 35
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- E2F_TARGETS+0.460
- G2M_CHECKPOINT+0.420
- MYC_TARGETS_V1+0.350
- MITOTIC_SPINDLE+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.210
- SPERMATOGENESIS+0.200
- NOTCH_SIGNALING+0.160
- KRAS_SIGNALING_DN+0.110
- DNA_REPAIR+0.100
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.490
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.470
- OXIDATIVE_PHOSPHORYLATION-0.430
- CHOLESTEROL_HOMEOSTASIS-0.420
- ADIPOGENESIS-0.400
- ALLOGRAFT_REJECTION-0.400
- COMPLEMENT-0.390
- COAGULATION-0.380
- ESTROGEN_RESPONSE_LATE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QB84TBA3 | high-grade glioma | — | 0.899 |
| 2 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.898 |
| 3 | TCGA-E2-A158-01A-11R-A12D-07 | — | E | 0.897 |
| 4 | TCGA-B6-A0IQ-01A-11R-A034-07 | — | E | 0.895 |
| 5 | TCGA-46-6026-01A-11R-1820-07 | — | cohortSQ1 | 0.894 |
| 6 | s0095110 | — | — | 0.894 |
| 7 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.893 |
| 8 | b2e80b2b-559c-424e-837d-fa1de6b912e7 | — | — | 0.893 |
| 9 | SRR10899976 | — | — | 0.891 |
| 10 | BS_3V3KE3VT | medulloblastoma | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |